

Amendment to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

1. (Currently amended) A complex of an amphiphilic copolymer with a bioactive agent, wherein the amphiphilic copolymer has benzoyl sulfonic acid groups on the hydrophobic segment of said copolymer.

2. (Currently amended) ~~[[The]]~~ A complex according claim 1, wherein said complex forms micelles in aqueous media.

3. (Original) A complex according to claim 1, wherein the amphiphilic copolymer is comprised of a hydrophilic polymer selected from the group consisting of: a polyalkylether, dextran, dextran, carboxymethyldextran, dextran sulfate, aminodextran, cellulose, carboxymethyl cellulose, chitin, chitosan, succinyl chitosan, carboxymethylchitin, carboxymethylchitosan, hyaluronic acid, a starch, an alginate, chondroitin sulfate, albumin, pullulan, carboxymethyl pullulan, polyglutamic acid, polylysine, polyaspartic acid, HPMA, styrene maleic anhydride copolymer, divinylethyl ether maleic anhydride copolymer, polyvinyl pyrrolidone, and polyvinylalcohol.

4. (Currently amended) A complex according to claim 1, wherein the ~~[[amphiphilic]]~~ amphiphilic polymer is a block copolymer made of hydrophilic and hydrophobic polymers.

5. (Original) A complex according to claim 4, wherein the hydrophilic polymer is polyoxyethylene glycol, polyoxypropylene glycol, polyoxyethylene/propylene glycol, dextran, carboxymethyldextran, dextran sulfates, aminodextran, cellulose, carboxymethyl cellulose, chitin, chitosan, succinyl chitosan, carboxymethylchitin, carboxymethylchitosan, hyaluronic acid, a starch, an alginate, chondroitin sulfate, albumin, pullulan, carboxymethyl pullulan, polyglutamic acid,

polylysine, polyaspartic acid, HEMA, styrene maleic anhydride copolymer, divinylethyl ether maleic anhydride copolymer, polyvinyl pyrrolidone, and polyvinylalcohol.

6. (Original) A complex according to claim 5, wherein the hydrophilic polymer is polyethylene glycol.

7. (Currently amended) A complex according to claim 6, wherein the polyethylene glycol has a molecular weight of about 1000-10000.

8. (Original) A complex according to claim 1, comprising a hydrophobic polymer, wherein the hydrophobic polymer is selected from a poly(alpha-hydroxy acid), polydioxanone, a polycarbonate, a polyanhydride, a polyorthoester, and a hydrophobic derivative of a poly(alpha-amino acid).

9. (Original) A complex according to claim 8, wherein the hydrophobic polymer is polylactic acid.

10. (Currently amended) A complex according to claim 1, wherein the ~~[[bioactive]]~~ bioactive agent is selected from the group consisting of topotecan, doxorubicin, adriamycin, vincristine, cisplatin, and a combination thereof.

11. (Original) A complex according to claim 1, wherein the bioactive agent is topotecan.

12. (Original) A method of treating a cancer comprising administering an effective amount of the complex according to claim 1 to a patient in need thereof.

13. (Currently amended) ~~[[A method]]~~ A method of treating osteo arthritis, rheumatoid arthritis, diabetic retinopathy, hemangiomas or psoriasis comprising administering an effective amount of the complex according to claim 1 to a patient in need thereof.

14. (Original) A complex of an amphiphilic copolymer with a contrast agent, wherein the amphiphilic copolymer has benzoyl sulfonic acid groups on the hydrophobic segment of said copolymer.

15. (Original) A method of diagnostic imaging comprising administering an effective amount of the complex according to claim 14 to a patient in need thereof.

16. (Currently amended) A process of making an amphiphilic copolymer having benzoyl sulfonic acid groups by reacting the amphiphilic copolymer with ~~[[sulfobenzoic]]~~ sulfobenzoic anhydride either in the melt or in solution.